Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945685 | 0.88 | GAA (0.77) | GAASMN1; SMN2KMT2AL3MBTL1HSD11B1 | |
| SCHEMBL12761000 | 0.84 | GAA (0.78) | GAASMN1; SMN2KMT2AL3MBTL1LMNA | |
| SCHEMBL1946162 | 0.84 | GAA (0.78) | GAASMN1; SMN2L3MBTL1LMNAPOLB | |
| SCHEMBL735124 | 0.82 | LMNA (0.66) | GAASMN1; SMN2MEN1KMT2AHSD11B1 | |
| SCHEMBL1945534 | 0.81 | GAA (0.72) | GAASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL14777927 | 0.81 | HSD11B1 (0.53) | GAASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL735481 | 0.81 | CNR1 (0.67) | GAASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL752734 | 0.81 | L3MBTL1 (0.65) | GAASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL17953064 | 0.80 | GAA (1.00) | GAASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL751828 | 0.80 | ALDH1A1 (0.66) | GAASMN1; SMN2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | GAA 517/4885SMN1; SMN2 2605/4885MEN1 989/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | GAA 517/4885SMN1; SMN2 2605/4885MEN1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.